The team led by Stefan Engelhardt, Professor of Pharmacology and Toxicology, has developed an RNA-based active ingredient called RCS-21 to prevent severe lung inflammation and fibrosis, i.e. scarring of the lung tissue, for example in SARS-CoV2 infections.
In the cell, RCS-21 stops the activity of the molecule microRNA 21. This nucleic acid, which Engelhardt and his team have been researching for a long time, is one of the triggers for the excessive activity of macrophages in severe lung infections.
In the scientific journal "Nature Communications", the team now describes how the active substance RCS-21 is delivered to its target particularly effective via an inhaler. To do this, the researchers took advantage of a special feature of macrophages. These scavenger cells are also present in large numbers in the healthy lung. There, they perform the important task of destroying bacteria and fungal spores as quickly as possible. The macrophages identify their targets among other things based on complex sugar molecules on the surface of the invaders. "We have determined in single cell analyses that the corresponding sugar receptors are, on the one hand, among the most common receptors on macrophages," says Stefan Engelhardt. "On the other hand, the receptors are, in a sense, a unique feature of macrophages – they hardly occur anywhere else."
Therefore team coupled its active ingredient to a sugar molecule, or more precisely: to trimannose. This approach had so far only been pursued with chemically less complex active ingredients. Studies with mice produced clear results. "When the drug was administered as a spray, macrophages took up the active ingredient significantly better than without sugar molecules. In contrast, other cell types even outright exclude the molecules," says Christina Beck, first author of the article together with Deepak Ramanujam.
In experiments with mice, RCS-21 ensured that microRNA 21 was reduced by more than half compared to control animals. Fibrosis and inflammation were also significantly reduced after treatment. Increased microRNA-21 activity was also stopped by treatment with RCS-21 in samples of human lung tissue infected with the SARS-CoV-2 coronavirus in the laboratory.
Studies to prove the drug's safety are already underway, the first clinical trials in humans are targeted for 2024. Responsibility lies with RNATICS, a TUM spin-off. In 2021 the start-up received around 7 million euros in funding from the German Federal Ministry of Education and Research (BMBF) to support the development of the drug.
RNATICS co-founder Stefan Engelhardt sees great potential in the mannose technology: "We were able to show that nucleic acid-based active substances can be used in a very targeted manner, at least in the lungs. This technology opens up a wide field for the development of novel RNA-based drugs. I expect a lot to happen in this area in the next few years."
Publication:
Trimannose-coupled antimiR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damage. Beck, C., Ramanujam, D., Vaccarello, P. et al. Nat Commun 14, 4564 (2023).
Source: Press release TUM
On 6th July, 2023, 140 researchers from the Munich site of all eight German Centers for Health Research (DZG) met at the 1st DZG Munich Day. Presentations, posters and a panel discussion provided participants with an overview of the structures and scientific highlights of the individual DZG and an insight into DZG-overarching collaboration.
Prof. Martin Hrabě de Angelis (DZD Board and Helmholtz Munich) opened the event on behalf of all Munich DZG site spokespersons. Minister of State Markus Blume (Bavarian State Ministry of Science and Art), Prof. Matthias Tschöp (CEO Helmholtz Munich and Vice-President of the Helmholtz Association for the Research Field Health) and Prof. Thomas Gudermann (Dean of the Medical Faculty of LMU Munich) presented the importance of the DZG in greeting speeches and underlined the importance of interdisciplinary collaboration.
As this year's chair of the DZG board, Prof. Martin Hrabě de Angelis presented the structures created for DZG-wide collaboration, such as the DZG Innovation Fund for the promotion of cross-disciplinary projects, a joint office and the DZG working groups. The working groups on research IT, promotion of early career researchers, patient involvement, public relations, regulatory aspects of clinical trials, global health and biobanking each involve experts from all DZG in order to jointly advance these topics across diseases.
In short overview presentations by the Munich site spokespersons, the excellent research in the individual DZGs as well as the variety of already existing collaborations between the DZGs at the Munich site became apparent.
This was followed by exciting translational highlights ranging from promising fundamental findings in health research to novel diagnostic and therapeutic approaches. Prof. Tobias Feuchtinger (DZIF) also presented the first results of the joint DZG Innovation Fund project "Cell and Gene Therapy", which involves scientists from DKTK, DZD, DZHK, DZIF and DZL.
In his keynote lecture, Prof. Julien Gagneur (TUM) presented the pioneering concept of the "Bavarian Cloud for Health Data" for data processing. The audience showed great interest in an exchange.
In a concluding panel discussion of the Munich DZG site spokespersons, ideas and success factors were collected to further promote the exchange between the different DZG centers. The audience also participated actively in a survey on ideas on how to strengthen collaborations within the DZG in Munich. For example, a platform or lecture series on existing infrastructures could be established. Scientific networking events such as the DZG Munich Day were described as very profitable and for the promotion of early career scientists with regard to translational research, participation in DZG-wide events was considered to be very valuable.
The conclusion of this very successful event was that the DZG scientists consider a regular cross-DZG exchange to be very beneficial and profitable in order to strengthen the many already existing collaborations between the DZGs in Munich, to further develop synergies and to establish new contacts.
DZNE is augmenting its nationwide infrastructure for clinical research with the construction of new facilities at several sites. To this end, the Helmholtz Association is providing around 35 million euros. This is intended to expand the capacities for interventional trials and advance the development of drugs against neurodegenerative diseases such as Alzheimer’s, Parkinson’s and ALS.
Neurodegenerative diseases can cause dementia, trigger movement disorders and massively impair health also in other ways. In Germany, more than two million people are currently living with these effects. As yet, there is no prospect of cure or at least of stopping the disease process. Current therapies can only alleviate symptoms and somewhat slow down disease progression. “We urgently need more effective drugs against dementia and other consequences of neurodegeneration,” said Prof. Pierluigi Nicotera, Chairman of DZNE’s Executive Board. “The expansion of DZNE’s clinical network, which has now been approved, creates a multisite infrastructure for early interventional trials with promising agents that will be tested for the first time in humans. In the field of neurodegenerative diseases, this is unparalleled in Germany and internationally. This is an important step in accelerating the search for therapies against neurodegeneration. There is no doubt that industry plays an important role in drug development. However, on the part of science, we must drive this development and take the initiative.”
At five DZNE sites – in Dresden, Magdeburg, Munich, Rostock and Tübingen – new buildings with so-called Clinical Trial Units (CTUs) will be constructed by 2028, equipped with rooms for treatment, facilities for inpatient monitoring and the necessary medical equipment. Together with the existing CTU in Bonn and facilities at DZNE’s Ulm site, this will establish a nationwide network for testing innovative therapeutic approaches. A new chapter is thus being opened, because until now DZNE has had to focus mainly on observational trials. Such studies are concerned, for example, with early detection or with understanding disease progression. “For years, we have been conducting inter-site studies together with local university hospitals. To this end, we have set up a highly effective study management that ensures examinations according to uniform criteria at all sites,” explained Prof. Thomas Klockgether, Director of Clinical Research at DZNE. “However, our options for interventional studies have been very limited up to now. They will now be significantly expanded. For the operation of the newly created CTUs, we will continue to work closely with the local university hospitals.”
DZNE will focus on so-called phase I and phase II trials. Such clinical studies, in which agents are tested on humans for the first time, are important steps on the path to new drugs. Frequently, they are run by research institutes. Pharmaceutical companies mainly focus on later phase III trials as they often consider the chances of success in early trials to be too uncertain. “We want to test new compounds that have yielded promising results in the laboratory on small groups of people. On our own or with financial support from the pharmaceutical industry. Generally, our aim is to initiate developments where industry may still be hesitant,” said Klockgether. DZNE is already collaborating with pharmaceutical companies and expects the expansion of its clinical network to provide a significant boost to such ventures. “The resources that are now being created make DZNE even more attractive as a partner for industry collaborations. Because in addition to scientific expertise, we can now also contribute an excellent infrastructure for interventional studies. This is very important for Germany as a hub for research.”
More than 8,000 individuals are currently enrolled in DZNE studies. Participants in interventional studies could be recruited from this large collective. In addition, there is another asset: so-called stratification, whose potential has not yet been fully utilized. Until now, most interventional studies on neurodegenerative diseases have included participants on rather broad bases. However, it is becoming increasingly clear that there are individual differences in many neurodegenerative diseases and that treatment should also be based on the stage of disease. “The bottom line is that you have to classify patients into groups according to scientific criteria and tailor therapy to these groups for the best possible chances of success,” Klockgether explained. Such a categorization – called “stratification” – is a standard procedure at DZNE, as participants in clinical studies are comprehensively characterized medically. “Insofar, on the one hand, we have a large pool of potential study subjects, since we conduct research across sites and are not limited to local collectives. On the other hand, our study subjects are stratified. Taken together, these are very good premises for testing new agents and providing significant momentum to drug development. This gives us the opportunity to play at the top internationally,” said Klockgether.
Can a human organ be mapped on a single-cell level to learn about the functionality of each individual cell? And can we learn how different these cells are from person to person? DZL researchers at Helmholtz Munich and their collaborators have taken up this challenge and developed the Human Lung Cell Atlas using artificial intelligence (AI)-based techniques. This atlas elucidates the diversity of single lung cell types and allows learning about lung biology in health and disease. It is the first major integrated organ and was built as part of the Human Cell Atlas (HCA) initiative, a worldwide collaborative effort to map the entire body at the level of single cells. The results were now published in Nature Medicine.
Single-cell technologies, developed in the past decade, enable researchers to study tissues at the resolution of individual cells, giving insight into the different functions of cells that make a whole organ do its job. However, generating a single-cell dataset is time-consuming and expensive, and generally, only a few individuals are included in each study. An international team of researchers now created a single-cell atlas of the human lung by combining 49 different published and newly generated datasets. This provided insight into the wide variety of cells and cell types existing in our lungs.
Prof Fabian Theis, Head of the Computational Health Center, Director of the Institute of Computational Biology at Helmholtz Munich and Professor at the Technical University of Munich (TUM), explains the project: “We have created a first integrated reference atlas of the human lung, which includes data from more than a hundred healthy people and reveals how the cells from individuals vary with age, sex, and smoking history. The sheer numbers of cells and individuals involved now gives us the power to see rare cell types and identify new cell states that have not previously been described.” Dr Malte Lücken, Group leader at the Institute of Computational Biology and the Institute of Lung Health & Immunity at Helmholtz Munich adds: “A comprehensive organ atlas requires many datasets to capture the diversity between both cells and individuals, but combining different datasets is a huge challenge. We developed a benchmarking pipeline to find the optimal method to integrate all datasets into the atlas, using artificial intelligence, and combined knowledge and data from almost 40 previous lung studies.”
While the core of the Human Lung Cell Atlas is data from healthy lungs, the team also took datasets from more than 10 different lung diseases and used machine learning to project these onto the healthy data, in order to understand disease states. It thereby offers a uniquely rich picture of how diseased lungs differ from healthy ones and provides pointers for potential therapeutic targets.
Prof Martijn Nawijn, a senior author on the paper and Professor at the University Medical Center Groningen, the Netherlands, said: “This is the first effort to compare healthy and diseased lungs in one study in an integrated way. Our study not only supports the presence of lung fibrosis in COVID-19, it allows us to identify and define a shared cell state between lung fibrosis, COVID-19 and lung cancer patients. Finding these shared disease-associated cells is really exciting, and reveals a totally different way of looking at lung diseases, opening possibilities for novel treatment targets and developing treatment response biomarkers. Our findings also suggest that therapies working for one disease may help alleviate others.”
By pooling and integrating all the bits of knowledge and data that had been generated previously, the researchers created the first integrated Human Lung Cell Atlas: For each of the 2.4 million cells in this atlas, they know which genes were active in which cell, thereby learning about the functionality of those cells. This enabled studies of how the cells from individuals vary with age, sex, or disease. For example, first author Lisa Sikkema from the Institute of Computational Biology and the scientific team saw that monocyte-derived macrophages (a specific type of immune cell) showed activity of similar genes in cancer, COVID-19, and lung fibrosis, likely playing a role in scar formation in the lung in all three diseases. Therapies working in one disease may therefore also be effective in mitigating the others. Sikkema remarks: “One of the big problems in creating the integrated lung cell atlas was with cell type annotation. Different research groups used different names for the same cell type, or the same name for different cells, so as a team we worked to standardize them using the data in the atlas. The atlas is a first step towards a consensus annotation of the human lung, which will help bring together the field of lung research.”
The Lung Atlas Integration project was a large collaborative effort with nearly 100 partners from more than 60 departments involved internationally, including key researchers from the University Medical Center Groningen and Northwestern University. The team is part of the Human Cell Atlas Lung Biological Network, which has its roots in the Chan Zuckerberg Initiative Seed Networks for the HCA, and the European Union funded lung network DiscovAIR. At the start of the pandemic in 2020, the single-cell lung communities came together rapidly, forming the HCA Lung Biological Network to help understand COVID-19, which then catalyzed the effort to integrate all the data.
The researchers made the atlas fully publicly available, and it is expected to serve as a central resource for doctors and scientists that want to better understand lung biology in health and disease and develop further studies. Dr Alexander Misharin, a senior author on the paper and Associate Professor of Medicine at Northwestern University Feinberg School of Medicine, USA, said: “The Human Lung Cell Atlas is a huge resource for the scientific and medical community. Openly available to researchers, new disease data can be mapped onto the HLCA, transforming research into lung biology and disease. As the first whole reference atlas of a major organ, the HLCA also represents a milestone towards achieving a full Human Cell Atlas which will transform our understanding of biology and disease and lay the foundation for a new era of healthcare”.
Altogether, the Human Lung Cell Atlas serves as the first example of how large-scale human cell atlases can progress current and future research on human health and disease.
Jointly against common diseases! This is the mission of the German Centers for Health Research (DZG). Their scientists are working to optimize the translation of research results into patient care and thus significantly improve the prevention and treatment of these diseases.
Now the time had come: project start for the winners of this year's DZG-overarching research projects in Dresden. The winners were honored at the German Center for Neurodegenerative Diseases (DZNE) Dresden by Prof. Gerd Kempermann and Prof. Michele Solimena.
In addition to the annual joint symposium, the 2023 start-up grants for cross-DZG projects also proved very popular. The aim of this funding is to enable new translational activities between the DZGs in Dresden that arise at the thematic interfaces of the centers.
This year, three project teams were awarded 10,000 euros of start-up funding:
Diabetes, cancer and dementia: as different as these diseases may appear, there are often crosslinks that are relevant for the development of therapeutic approaches and investigative methods. The active networking of different DZGs thus reflects a unique opportunity to develop completely new and innovative research approaches. Dresden is a pioneer in this respect, as the three DZGs based in Dresden, the German Cancer Consortium (DKTK), the Paul Langerhans Institute Dresden (PLID) of the German Center for Diabetes Research (DZD) and the aforementioned DZNE, have already been closely networked for several years.
The DZG Science & Career Day on 12 and 13 June 2023 brought together 100 young scientists at the Urania in Berlin to discuss the topic of "Translational Health Research". Six German Centres for Health Research (DZG) organised the event for the first time. Lectures and workshops provided the participants with important impulses for their careers. The programme also included scientific and personal networking between researchers from the different DZGs.
Prof. Martin Hrabě de Angelis (DZD and Helmholtz München), acting spokesperson of the DZG, and Dr. Ute Petereit (Federal Ministry of Education and Research, BMBF) opened the two-day event. Petereit emphasised the role of promoting young researchers as one of the central pillars in the foundation of the DZG. Hrabě de Angelis gave an overview of successes in translational research and underlined: "The DZGs are closely networked. On the scientific level, for example, in joint projects of the DZG Innovation Fund and in six working groups, such as the working group for the career development of young scientists, which organised this event".
Translational research - how does it work?
On the first day, the focus was on research, with a panel discussion on what is meant by translational research in general - surprisingly, with different emphases depending on the professional background of the discussants. The audience also participated actively, asking questions such as how the DZG could provide more sustainable career paths and how young scientists themselves could promote translational research in the health sciences. The panellists said: "If you love science, do it - go where your heart is!”
Spin-offs and product developments as successful translation models
DZG researchers Prof. Martin Witzenrath (DZL, Charité Berlin), Prof. Patrick Most (DZHK, University Hospital Heidelberg and InoCard GmbH) and Prof. Nicole Fischer (DZIF, University Hospital Hamburg-Eppendorf) presented their personal models for success in translational medical research. They also shed light on the tension between business and science from different perspectives. All three reported on their experiences with spin-offs and product development, i.e. successful translation. Most emphasised the importance of starting with the product in mind. You also had to keep in mind the perspective of potential venture capitalists: If you could show that some patients need a certain therapy and that you could make money with it, you can win them over. Witzenrath agreed that it is difficult in Germany to get money to test your ideas, especially in early clinical trials. Most also coined the term "intrapreneurship": the possibility of continuing one's own developments from academic work, for example in a spin-off company. If you want to go in this direction, you need to be aware of the regulatory aspects at an early stage and develop an eye for patents.
In the final session of the first day, participants of the DZG Science & Career Day presented their own scientific projects in short talks and posters.
Interactive workshops for personal career development
The second day's programme focused on career opportunities in translational research. Roman Rehor from the organisation "Young Entrepreneurs in Science" gave a talk on entrepreneurship in science. The subsequent workshops covered career-related topics. As one participant pointed out, "The personal advice and different perspectives of the speakers gave me good direction and ideas for my own career".
The conclusion of the event was that the right mindset, an interdisciplinary network and the enthusiasm of the young scientists contribute decisively to the goal of translational research, i.e. the rapid transfer of research results into medical application.
The heart is much more than a pump and the vessels much more than transport routes: together they form a communication centre that exchanges information with all other organs. These complex communication signals have hardly been researched so far - even though they play a major role in determining whether our organs stay healthy or get sick. The newly founded Helmholtz Institute for Translational AngioCardioScience (HI-TAC) in Mannheim and Heidelberg aims to change this.
The Helmholtz Senate decided yesterday that HI-TAC will begin work in July 2023. Following a start-up phase, the annual budget will be around 5.5 million euros from 2028. The money will be provided by the Helmholtz Association, the Max Delbrück Centre, the state of Baden-Württemberg and the University of Heidelberg. In addition to a new six-storey research building in Mannheim and new rooms in Heidelberg, there will also be co-working stations for exchange between Heidelberg, Mannheim and Berlin.
Scientists will explore how communication within the cardiovascular system and at its interfaces with the nervous and immune systems and metabolism can be harnessed to ensure that our organs remain healthy throughout life and that we can age healthily. "Diseases of the inner lining of the blood vessels are directly or indirectly responsible for two thirds of all deaths," says Professor Hellmut G. Augustin, designated founding director of HI-TAC. The way in which the condition of the blood vessels and the heart changes should serve as a kind of early warning system: It indicates whether health is at risk and should be counteracted with targeted therapies long before symptoms appear.
"By combining the individual strengths of the researchers at the MDC in Berlin and the University of Heidelberg, HI-TAC will become a driver of translation, including the early development of new drug candidates," says Prof. Dr. Johannes Backs, spokesperson of the DZHK Heidelberg/Mannheim site and Director of the Institute of Experimental Cardiology at the Medical Faculty of the University of Heidelberg. "Concepts are being developed with the aim of improving systemic health. In the future, we want to stop pathogenic signals that originate in the heart and blood vessels in order to prevent damage to other organs.
The DZHK is one of several partners, including the European Centre for Angioscience at the University Medical Centre Mannheim (ECAS), the Department of Cardiology and Experimental Cardiology at Heidelberg University Hospital, the Berlin Institute for Health at the Charité (BIH) and the Charité - Universitätsmedizin Berlin.
The DZNE study „Identifikation relevanter psychosozialer Faktoren in der Entstehung, Behandlung und Versorgung von Menschen mit Demenz“ investigates the effect of different measures in the treatment of people suffering from dementia. Its key finding is that people affected by dementia who are cared for in their familiar environment and are socially integrated show better disease progression. The study was funded by the German Federal Ministry for Family Affairs, Senior Citizens, Women and Youth (BMFSFJ).
Lisa Paus, Federal Minister for Family Affairs: "A diagnosis of dementia means drastic changes not only for those affected, but also for their relatives. The results of the study clearly show that when caring for people with dementia, we must focus not only on medical aspects but also on social aspects. As a society, we must do everything we can to ensure that dementia patients can live independently and self-determinedly in their familiar homes for as long as possible and are involved in social activities. It is important that people with dementia and their relatives feel valued and noticed. As the German Federal Ministry for Family Affairs, for example, we are promoting local alliances for people with dementia as part of the German government's "National Dementia Strategy" with the aim of improving networking between local players in order to develop suitable services together with those affected."
The results of the study provide important indications for a good living together with people with dementia as well as for their healthcare and therapy: According to the findings, the individual's living environment plays a particularly important role for those persons. Good and regular social contacts, especially joint activities that promote social interaction and allow people with dementia to actively participate in everyday life, have a positive effect on dementia symptoms. The study's findings confirm studies from abroad that had previously suggested similar results.
In their work, the DZNE researchers involved nursing and medical care staff, volunteers, and family caregivers in focus group discussions.
Prof. Dr. Wolfgang Hoffmann, speaker of the DZNE site Rostock/Greifswald: "The intensive discussions with the study participants confirm that psychosocial factors are of great importance - both for the quality of life and for the autonomy and social participation of people with dementia. If psychosocial aspects are strengthened in a targeted manner, this positively influences the course of the disease and supports family caregivers."
Study coordinator Dr. Francisca S. Rodriguez: "An enabling, appreciative, and loving social environment can further enhance the positive effects of psychosocial interventions."
The researchers derived concrete operational recommendations from the results of the focus group discussions. According to these, it is important to initiate model projects that strengthen "positive social contacts of people with dementia." There is also a need for social awareness and support for family members to create an understanding of dementia symptoms. In practice, however, many approaches fail due to a lack of trained personnel and also long distances and corresponding transportation options. "Nevertheless, the next important step would be to develop concrete practical ways to integrate the most demonstrably effective psychosocial interventions into dementia care," the authors conclude.
In order to facilitate a long independent and self-determined life for people with dementia in their own homes, concrete measures are already being implemented in the National Dementia Strategy of the Federal Government to better integrate those affected into society and to provide stronger support for family members.
The transcription factor SNAIL is an old acquaintance in the context of the spread of tumors. Scientists from the German Cancer Consortium (DKTK) and the Technical University of Munich (TUM) are now publishing a previously undescribed function of the factor: in a specific form of pancreatic cancer, SNAIL dramatically accelerates cancer growth by driving the cell cycle and bypassing senescence. These newly discovered functions of SNAIL in laboratory experiments may be curbed by targeted agents.
Cancer of the pancreas still has an extremely poor prognosis: barely ten percent of patients survive the first five years after diagnosis. Doctors and scientists are therefore urgently looking for new ways to stop the disease more successfully than before. In this context, they are looking for subtypes of the disease that differ in their response to agents on the basis of certain molecular properties.
Dieter Saur, DKTK Professor of Translational Cancer Research at the DKTK partner site of the Technical University of Munich, is investigating the role of the transcription factor SNAIL in the development and progression of various tumors. About 70 percent of all pancreatic cancers overexpress SNAIL - as do numerous other cancers. It is known that SNAIL triggers a developmental program in cells known as "EMT," which increases the aggressiveness of tumors and promotes metastasis. In this process, the cells transform from so-called epithelial cells into a connective tissue-like developmental stage called mesenchymal cells.
Based on previous experiments, Saur and colleagues suspected that in certain cases SNAIL may also drive cancer through other molecular signaling pathways. To confirm this suspicion, Saur's team examined the role of SNAIL in different types of cancer, using both mouse models and human tumor cell lines, which differed in their primary genetic driver mutations.
While SNAIL overexpression was actually rather protective in certain intestinal tumor models, it dramatically accelerated tumor growth in pancreatic cancers driven by the KRAS oncogene. However, the cancer cells do not exhibit the molecular hallmarks of the EMT program. Instead, SNAIL acts like a classical oncogene in these tumors, accelerating the cell cycle and preventing cancer cell senescence.
"This newly discovered function of SNAIL may open up new therapeutic possibilities," explains Dieter Saur. "In recent years, several new agents have been approved that block key cell cycle molecules. It may be worthwhile in patients with KRAS-driven pancreatic cancer and SNAIL overexpression to investigate whether targeted blockade of these molecules can improve therapeutic outcomes."
Original publication: Mariel C. Paul, Christian Schneeweis, Chiara Falcomatà, Chuan Shan, Daniel Rossmeisl, Stella Koutsouli, Christine Klement, Magdalena Zukowska, Sebastian A. Widholz, Moritz Jesinghaus, Konstanze K. Heuermann, Thomas Engleitner, Barbara Seidler, Katia Sleiman, Katja Steiger, Markus Tschurtschenthaler, Benjamin Walter, Sören A. Weidemann, Regina Pietsch, Angelika Schnieke, Roland M. Schmid, Maria S. Robles, Geoffroy Andrieux, Melanie Boerries, Roland Rad, Günter Schneider and Dieter Saur: Non-canonical functions of SNAIL drive context-specific cancer progression. Nature Communications 2023, DOI: 10.1038/s41467-023-36505-0
Source: DKTK (original press release DKFZ)
More than 100 scientists from Dresden exchanged views on commonalities in research on diabetes, cancer and neurodegenerative diseases.
A total of more than 80 institutions with numerous participating universities, university hospitals and non-university research facilities make up the German Centers for Health Research. Three of them have partner sites in Dresden. These include the German Cancer Consortium (DKTK), the German Center for Neurodegenerative Diseases (DZNE) and the Paul Langerhans Institute Dresden (PLID) of the German Center for Diabetes Research (DZD).
In the individual centers, the best scientists from university and non-university research institutions join forces in an interdisciplinary way to bring new medical research results faster into clinical application. This is urgently needed, as the number of people suffering from or newly diagnosed with widespread diseases such as cancer, metabolic or neurodegenerative diseases is still alarming.
Despite the different thematic priorities of the three centers, there are many commonalities with regard to the development of new therapeutic approaches or examination methods. Regular intensive and, above all, long-term interconnection at the Dresden site therefore offers excellent opportunities to jointly develop new innovative research strategies.
Once a year, the three centers organize the "Joint DZG Symposium Dresden", which celebrated its fifth anniversary on April 27 and this time was primarily hosted by PLID. The symposium, which was conceived as an exchange platform for scientists and physicians from Dresden, was able to take place again this year as a presence meeting with over 100 participants after several years of online events due to the Corona pandemic.
The welcome was given by Prof. Michele Solimena, site speaker of the PLID/DZD and Prof. Esther Troost, Dean of the Medical Faculty of TU Dresden, who unanimously underlined the importance of the DZG for the Johannstadt Life Sciences Campus of the Dresden University Medical School.
In his presentation on the national activities of the German Centers for Health Research, Martin Hrabé de Angelis, board member of the DZD and this year's chairman of the steering committee of the national DZG activities, spoke about the importance of a common research IT, the promotion of young researchers and patient: involvement for cooperation and the success of the DZG.
Since 2020, there have been popular and successful grants for the seed funding of DZG-overarching projects, which are intended to promote new translational activities among the Dresden DZGs. The following 2022 awardees presented their projects:
The results achieved in the three projects are convincing and provide a basis for further joint research activities.
This year's keynote lecture was given by Prof. Anthony Hyman, Managing Director of the Max Planck Institute for Molecular Cell Biology and Genetics, Dresden. The lecture by this multiple award-winning scientist focused on the cell as a polyphasic system and how the formation of fluid phases in a fluid cytoplasm affects the formation of membrane-less compartments of macromolecules in living cells. Excitingly presented, it will be remembered by the audience at the end not only because of the vivid "oil and vinegar" comparison.
At the end of the 5th Joint DZG Symposium, Prof. Mechthild Krause announced the call for the next round of DZG-overarching seed funding, in which at least two scientists from different DZGs can jointly submit a project proposal, and invited the participants to the 6th Joint DZG Symposium, which will be hosted by the DKTK in Dresden in 2024.
A whole range of diseases can be caused by the Epstein-Barr virus - EBV for short: various types of cancer are among them, immune diseases, multiple sclerosis or infectious mononucleosis, also known as glandular fever, which is a risk factor for multiple sclerosis. The start-up EBViously presented its EBV vaccine candidate at the World Vaccine Congress 2023 in the USA in April. The company is a spin-off of Helmholtz Zentrum München. The project leading to the spin-off was co-funded by the German Center for Infection Research (DZIF). Clinical testing of the vaccine candidate is scheduled to start in 2024.
Epstein-Barr virus is one of the nine known herpesviruses and one of the most common viruses found in humans. It is estimated that approximately 90% of the world´s population is infected with EBV. Infections typically occur in early childhood and are usually asymptomatic. However, when infections occur later in life, they frequently cause infectious mononucleosis (“glandular fever”) and other serious complications. The virus is also associated with certain cancers – approximately 200,000 cancer cases worldwide, including several types of lymphoma, are attributed to EBV. In addition, EBV infection is by far the most important risk factor for multiple sclerosis.
In Washington, DC, EBViously announced the first details of its vaccine candidate, called EBV-001. The vaccine could be used to prevent Epstein-Barr virus (EBV)-induced diseases in the future.
The vaccine is based on non-infectious EBV-derived virus-like particles (VLPs) that mimic the original viral pathogen and its complexity.
VLPs resemble actual virus particles, but do not contain any viral genetic material. With the authentic structure of the virus, these empty shells signal an EBV infection to the immune system and elicit a highly specific immune response from both the humoral and the cellular parts of the immune system.
“Based on our very favorable preclinical proof-of-concept data regarding the immunogenicity of the vaccine, we are confident that EBV-001 can effectively prevent the development of infectious mononucleosis and the often associated chronic fatigue syndrome,” says Axel Polack, M.D., designated CEO of EBViously. “A GMP process has been established by a commercial CMO and our goal is to begin clinical trials in 2024.”
“As a primary indication, we are targeting the prevention of infectious mononucleosis, also known as kissing disease or glandular fever, and post-infectious fatigue/chronic fatigue (ME/CFS), a common, long-COVID-like protracted disease following infectious mononucleosis,” says Prof. Wolfgang Hammerschmidt, designated CSO of EBViously. “Other potential indications include the prevention of post-transplant lymphoproliferative disease (PTLD) and EBV-associated cancers. As infectious mononucleosis is a known risk factor for multiple sclerosis, there is great hope that our vaccine may also reduce the incidence of this chronic neurodegenerative autoimmune disease.”
For major breakthroughs, the American Diabetes Association (ADA) awards its highest honor, the Banting Medal for Scientific Achievement named after the nobel laureate and discoverer of insulin, Frederick Banting. Helmholtz Munich CEO and Humboldt Professor at the Technical University of Munich (TUM), Prof. Dr. med. Dr. h.c. Matthias Tschöp, is now the first German to receive the prestigious award.
The mission of the ADA is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. The association now unveiled this year’s Award recipients. Matthias Tschöp, CEO of Helmholtz Munich and Helmholtz Vice President of Health Research, is the awardee of the 2023 Banting Medal for Scientific Achievement, the highest honor of the ADA.
This prestigious award recognizes significant, long-term contributions to the understanding, treatment, or prevention of diabetes. A special honor, since Tschöp is not only the first German scientist to receive this medal but also the youngest Banting Medalist to date. Inaugurated in 1941, the prize is given in memory of Sir Frederick Banting, a key discoverer of insulin and its therapeutic use.
Discovery of groundbreaking medicines for obesity and diabetes
Matthias Tschöp is a physician-scientist who has made a series of groundbreaking discoveries in the field of diabetes. In addition to the hunger hormone ghrelin which he identified in 2000, Tschöp and his long-term chemistry collaborator Richard DiMarchi discovered the therapeutic class of dual and triple gut hormone drugs, the so-called polyagonists. Their research resulted in a novel class of drugs, which have been approved in the USA last year. There are a further ten polyagonists currently in clinical trials, promising a new era of metabolic medicine.
For the first time, the widespread diseases of overweight and obesity can be effectively treated with these novel drugs, thereby significantly reducing the risk of developing diabetes. The discoveries of Matthias Tschöp have contributed substantially to advance the field of diabetes care and research and have significantly transformed the fight against the disease.
A prestigious award
Matthias Tschöp is one of the few international recipients of the highest honor of the American Diabetes Association. The ADA will recognize his world-leading academic achievements at 83rd Scientific Session of ADA on June 23-26, 2023, in San Diego (USA). It is the world’s largest scientific meeting focused on diabetes research, prevention, and care, with more than 12,000 leading physicians, scientists, and healthcare professionals from around the world expected to convene to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes.
About the scientist:
Prof. Dr. med. Dr. h.c. Matthias H. Tschöp is CEO and scientific director at Helmholtz Munich, Alexander von Humboldt professor at the Technical University of Munich (TUM) and Helmholtz Vice President of Health Research.
Interview “Advancing the fight against obesity” with Matthias Tschöp
You are currently viewing a placeholder content from Google Maps. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from OpenStreetMap. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Mapbox. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from hCaptcha to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from Turnstile to submit the form. Please note that doing so will share data with third-party providers.
More Information